Acceleron Pharma Inc. (NASDAQ:XLRN) SVP John D. Quisel sold 5,113 shares of the stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $38.42, for a total transaction of $196,441.46. Following the sale, the senior vice president now directly owns 57,918 shares in the company, valued at $2,225,209.56. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) traded up 0.50% during trading on Thursday, hitting $39.94. 465,608 shares of the stock traded hands. Acceleron Pharma Inc. has a 52-week low of $23.07 and a 52-week high of $41.69. The firm’s market cap is $1.55 billion. The stock has a 50 day moving average of $35.47 and a 200 day moving average of $30.78.

Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.12). Acceleron Pharma had a negative net margin of 724.22% and a negative return on equity of 44.67%. The company had revenue of $3.10 million for the quarter, compared to analyst estimates of $3.69 million. During the same quarter last year, the company earned ($0.59) EPS. The business’s revenue was down 3.1% compared to the same quarter last year. Analysts expect that Acceleron Pharma Inc. will post ($2.70) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Acceleron Pharma Inc. (XLRN) SVP Sells $196,441.46 in Stock” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/09/14/acceleron-pharma-inc-xlrn-svp-sells-196441-46-in-stock.html.

Several institutional investors and hedge funds have recently bought and sold shares of XLRN. BlackRock Inc. increased its holdings in shares of Acceleron Pharma by 4,559.6% during the first quarter. BlackRock Inc. now owns 3,674,593 shares of the biopharmaceutical company’s stock valued at $97,266,000 after acquiring an additional 3,595,733 shares in the last quarter. Westfield Capital Management Co. LP increased its holdings in shares of Acceleron Pharma by 46.6% during the second quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock valued at $51,127,000 after acquiring an additional 534,440 shares in the last quarter. Sectoral Asset Management Inc increased its holdings in shares of Acceleron Pharma by 378.2% during the second quarter. Sectoral Asset Management Inc now owns 604,499 shares of the biopharmaceutical company’s stock valued at $18,371,000 after acquiring an additional 478,099 shares in the last quarter. AXA acquired a new position in shares of Acceleron Pharma during the second quarter valued at about $9,833,000. Finally, UBS Asset Management Americas Inc. acquired a new position in shares of Acceleron Pharma during the second quarter valued at about $9,747,000. Hedge funds and other institutional investors own 88.07% of the company’s stock.

Several brokerages recently commented on XLRN. Royal Bank Of Canada began coverage on shares of Acceleron Pharma in a research report on Thursday. They set a “sector perform” rating on the stock. UBS AG reissued a “buy” rating and set a $50.00 price objective (up from $36.00) on shares of Acceleron Pharma in a research report on Tuesday. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Acceleron Pharma in a research report on Tuesday, September 5th. Cann reissued a “hold” rating on shares of Acceleron Pharma in a research report on Tuesday, September 5th. Finally, ValuEngine raised shares of Acceleron Pharma from a “sell” rating to a “hold” rating in a report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Acceleron Pharma currently has a consensus rating of “Buy” and an average target price of $42.21.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.